Table 2.

Proyecto PreCancer RE-AIM quantitative and qualitative evaluation metrics.

RE-AIM dimensionQuantitative evaluation metric(s)Qualitative evaluation metric(s)
Reach% of eligible women screenedFGD/KII of women screened vs. unscreened
Preimplementation: VIAKAP survey
Postimplementation: HPV testing
Effectiveness% of women completing continuum of careClinical observation (counseling content and quality)
Preimplementation: % of screen-positive women attending colposcopy, % with colposcopy/histology-confirmed CIN2+ receiving treatmentTime-and-motion studies (36)
Postimplementation: % of screen-positive women attending TVT, % of ablation-eligible women receiving ablation, % of ablation-ineligible women attending colposcopy, and % of ablation-ineligible women receiving treatmentFGD/KII of women completing and not completing continuum of care
FGD/KII of staff delivering the program
Assess acceptability of receiving immediate treatment vs. triage management by women
Assess acceptability of self vs. clinician sampling, lack of visual exam at primary screen
Adoption% of midwives screening ages 30–49 women by HPV testingFGD/KII with high and low adopters of HPV testing
Compare %VIA/total screens to %HPV/total screens over time
ImplementationTime from sample collection to testing, result delivery to patient, result delivery to follow-up visit, etc.Time-and-motion studies
MaintenanceQuarterly change in reach and effectiveness measures over timeNote major events that can influence time trends (health strikes, flooding, transportation strikes, supply chain disruptions, political turnover)
Assess unexplained changes (increases or decreases) in reach and effectiveness measures
  • Abbreviations: TVT, Triaje Visual para Tratamiento; VIA, visual inspection with acetic acid.